SCHEMBL2177779

SCHEMBL2177779

Cc1cnc(NS(=O)(=O)c2ccc(N)cc2)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
ALDH1A1 P00352 4/20 0.62
CYP2C9 P11712 3/20 0.56
ADRA1A P35348 3/20 0.56
EDNRA P25101 3/20 0.56
TDP1 Q9NUW8 2/20 0.56
KDM4E B2RXH2 1/20 0.56
SLC6A4 P31645 1/20 0.56
PRMT6 Q96LA8 1/20 0.56
AKT1 P31749 3/20 0.55
CA12 O43570 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
CA3 P07451 1/20 0.54
CA6 P23280 1/20 0.54
CA5A P35218 1/20 0.54
CA9 Q16790 1/20 0.54
CA14 Q9ULX7 1/20 0.54
CA5B Q9Y2D0 1/20 0.54
MAPT P10636 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14921838 0.84 ALDH1A1 (0.54) LMNAALDH1A1CYP2C9KDM4ECA12
SCHEMBL2179405 0.81 KMO (0.58) ALDH1A1EDNRACA12CA1CA2
Sulfamethizole SCHEMBL26453 0.77 ALDH1A1 (1.00) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfamethizole SCHEMBL1566142 0.76 ALDH1A1 (0.97) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfamethizole SCHEMBL28693374 0.75 ALDH1A1 (0.94) LMNAALDH1A1CYP2C9ADRA1AEDNRA
SCHEMBL564521 0.74 ALDH1A1 (0.60) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfamethizole SCHEMBL9018487 0.74 ALDH1A1 (0.91) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfamethizole SCHEMBL9292378 0.74 ALDH1A1 (0.91) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfamethizole SCHEMBL580299 0.74 ALDH1A1 (0.91) LMNAALDH1A1CYP2C9ADRA1AEDNRA
Sulfaperin SCHEMBL151755 0.73 LMNA (0.70) LMNAALDH1A1CYP2C9ADRA1AEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10768157-B2 Materials and methods for the detection of trace amounts of substances in biological and environmental samples THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2020-09-08 US disclosed
EP-2998359-B1 METHOD FOR IMPROVING THE ELECTRICAL-INSULATING PROPERTY AND THE FOGGING RESISTANCE OF A POLYESTER RESIN COMPOSITION ADEKA CORP (JP) 2019-08-21 EP disclosed
US-20180059082-A1 MATERIALS AND METHODS FOR THE DETECTION OF TRACE AMOUNTS OF SUBSTANCES IN BIOLOGICAL AND ENVIRONMENTAL SAMPLES THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2018-03-01 US disclosed
US-20180059082-A1 MATERIALS AND METHODS FOR THE DETECTION OF TRACE AMOUNTS OF SUBSTANCES IN BIOLOGICAL AND ENVIRONMENTAL SAMPLES THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) 2018-03-01 US disclosed
EP-2484725-B1 POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN ADEKA CORP (JP) 2017-07-19 EP disclosed
US-20160115298-A1 MOLDED ARTICLE, INSULATING MATERIAL COMPRISING SAME, AND METHOD FOR IMPROVING ELECTRICAL-INSULATING PROPERTY OF POLYESTER RESIN COMPOSITION ADEKA CORPORATION (JP) 2016-04-28 US disclosed
EP-2998359-A1 MOLDED ARTICLE, INSULATING MATERIAL COMPRISING SAME, AND METHOD FOR IMPROVING ELECTRICAL-INSULATING PROPERTY OF POLYESTER RESIN COMPOSITION Adeka Corporation (JP) 2016-03-23 EP disclosed
US-20140001672-A1 POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN ADEKA CORPORATION (JP) 2014-01-02 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2013-01-24 US disclosed
EP-2484725-A1 POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN Adeka Corporation (JP) 2012-08-08 EP disclosed
US-20120189793-A1 POLYESTER RESIN COMPOSITION, POLYESTER FIBER, POLYESTER RESIN MOLDED ARTICLE, AND PROCESS FOR PRODUCTION OF NUCLEATING AGENT FOR POLYESTER RESIN ADEKA CORPORATION (JP) 2012-07-26 US disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed
WO-2011082400-A2 MODULATORS OF IMMUNOINHIBITORY RECEPTOR PD-1, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130022629-A1 Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof CD274, PDCD1LG2, PDCD1 LMNA 4797/4885ALDH1A1 380/4885CYP2C9 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.